Option chain shows key data for Oncolytics Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oncolytics Biotech.

Oncolytics Biotech (NASDAQ:ONCY) Stock, Option Chain

Oncolytics Biotech

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Screenshot 2024-08-13 at 5.40.41 PM

Biotech

General

ONCY

Extending Survival: Oncolytics Biotech&#39;s Pelareorep Shows Promise In Fighting Metastatic Breast Cancer

Screenshot 2024-07-29 at 6.05.52 PM

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment

Screenshot 2024-03-06 at 6.25.21 PM

Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC) Fights Cancer With Pelareorep, Which Has Received FDA Fast Track Designation For Breast And Pancreatic Cancer

Oncolytics Biotech Inc

Press Releases

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

Small Cap

Opinion

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Investors Eye Biotech Sector as Cancer Therapy Market Surges

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Comments

Oncolytics Biotech

Oncolytics Biotech (ONCY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga